September 10, 2009 — There are now published data from a phase 2 multicenter trial on the effectiveness of bevacizumab (Avastin, Genentech) in patients with glioblastoma who have progressed despite ...

One hundred sixty-seven patients were randomly assigned to receive bevacizumab 10 mg/kg alone or in combination with irinotecan 340 mg/m 2 or 125 mg/m 2 (with or without concomitant enzyme-inducing ...

Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study The Avastin in Glioblastoma trial has shown that patients ...

May 6, 2009 — The US Food and Drug Administration (FDA) has granted accelerated approval for bevacizumab (Avastin, Genentech) for use in patients with glioblastoma that has progressed despite previous ...

LOS ANGELES, May 15 (Reuters) - Results from a mid-stage trial showed treatment with Genentech Inc's Avastin improved survival for patients with recurring brain cancer, the company said on Thursday.

Boston Scientific (($BSX)) announced an update on their ongoing clinical study. Study Overview: The FRONTIER study, officially titled ‘A ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...

Human brain cells, classified into different groups according to gene expression (each color represents a group), are mapped back to their original locations in the human brain. A detailed analysis of ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...